Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R)-Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.98 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.98 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ondansetron SCHEMBL41455 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL17076602 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29607040 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (S)-Ondansetron SCHEMBL25017 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL7217414 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL25018 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL8153849 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29387592 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL27599152 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL157565 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2246 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120053385-A | Ondansetron hydrochloride tablet and preparation method thereof | 福安药业集团宁波天衡制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| CN-1833641-A | Preparation and technique of ondansetron hydrochloride oral liquor | YIKANGXING PHARMACEUTICAL CO L (CN) | 2006-09-20 | — | — | CN | claimed |
| WO-2006046253-A1 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | WO | claimed |
| CN-1709222-A | Gastric floating slow-release administrating system and its three-dimensional printing forming preparation method | UNIV HUAZHONG SCIENCE TECH (CN) | 2005-12-21 | — | — | CN | claimed |
| CN-1666747-A | Fructose injection of anti-tumor drug | YANG XIHONG (CN) | 2005-09-14 | — | — | CN | claimed |
| CN-1555795-A | Ondansijiong hydrochleride freeze dried powder ampoule for injection and its preparation method | 陈庆财 | 2004-12-22 | — | — | CN | claimed |
| CN-1529614-A | Method of reducing side effects of chemotherapy in cancer patient | ϣ������ҩ��˾ | 2004-09-15 | — | — | CN | claimed |
| EP-1339707-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-09-03 | — | — | EP | claimed |
| US-6440453-B1 | MIXTURE WITH TEA TREE OIL, ETHANOL AND WATER; SIDE EFFECT REDUCTION DURING CHEMOTHERAPY FOR CANCER AND/OR TUMORS | NOVOSIS PHARMA AG (DE) | 2002-08-27 | — | — | US | claimed |
| US-20020107275-A1 | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2002-08-08 | — | — | US | claimed |
| WO-2002036558-A2 | NOVEL CRYSTAL AND SOLVATE FORMS OF ONDANSETRON HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-05-10 | — | — | WO | claimed |